The Hidden Gap Between Phase III Success and Market Access: When Evidence Misalignment Delays Commercial Readiness
For many biopharma teams, Phase III is treated as the final mountain to climb. Once efficacy and safety are proven, commercial readiness is assumed to follow naturally. In reality, that assumption is ...
Japan’s Evolving HTA Landscape: What Global Launch Teams Must Know
Japan has quietly turned its HTA framework into one of the most influential, but often misunderstood, pricing systems in major markets. Since formal cost-effectiveness evaluation became part of the NH ...